6-Hydroxydopamine Induce Neurodegeneration In Terminally Differentiated SH-SY5Y Neuroblastoma Cells Via Enrichment Of The Nucleosomal Degradation Pathway: A Global Proteomic Approach

The SH-SY5Y human neuroblastoma cells have been used for decades as an in vitro cell model of dopaminergic neurons to explore the underlying science of cellular and molecular mechanisms of neurodegeneration in Parkinson’s disease (PD). However, data revealing the protein expression changes in 6-OHDA induced cytotoxicity in differentiated SH-SY5Y cells remain void. Therefore, we investigated the differentially regulated proteins expressed in terminally differentiated SH-SY5Y cells (differ-SH-SY5Y neural cells) exposed to 6-hydroxydopamine (6-OHDA) using the LC-MS/MS technology and interpreted the data using the online bioinformatics databases such as PANTHER, STRING, and KEGG. Our studies demonstrated the neuronal development in differ-SH-SY5Y neural cells was implicated by the overexpression of proteins responsible for neurite formations such as calnexin (CANX) and calreticulin (CALR) besides signicant down-regulation of ribosomal proteins. The enrichment of the KEGG ribosome pathway was detected with signicant down-regulation (p < 0.05) of all the 21 ribosomal proteins in differ-SH-SY5Y neural cells compared with undifferentiated cells. Whereas in the PD model, the pathological changes induced by 6-OHDA were indicated by the presence of unfolded and misfolded proteins, which triggered the response of 10 kDa heat shock proteins, namely HSPE1 and HSPA9. Moreover, the 6-OHDA induced neurodegeneration in differ-SH-SY5Y neural cells also upregulated the voltage-dependent anion-selective channel protein 1 (VDAC1) protein and enriched the KEGG systemic lupus erythematosus pathway that was regulated by all 17 histone proteins (p < 0.05) in differ-SH-SY5Y neural cells. These results suggest the central event in the neurodegenerative mechanism induced by 6-OHDA in the PD cell model was the nucleosomal degradation in the KEGG-SLE pathway indicated by the increased histone release in the apoptotic cells. we performed label-free global protein proling of terminally differentiated cells and the cell model of PD using 6-hydroxydopamine-induced neurodegeneration of differ-SH-SY5Y cells based on a shotgun proteomic methodology. The main objective of this study was to identify the novel biomarkers and pathways involved in the neuronal development of SH-SY5Y cells and the cellular model of PD. The functional role and enriched canonical pathway of the differentially expressed proteins identied from these studies were further explored using bioinformatic tools. This study further authenticates the use of the 6-OHDA induced cytotoxicity on differ-SH-SY5Y cell model as an important tool in the investigation of potential drug targets for PD.


Introduction
Over the last 20 years, a signi cant amount of data has emerged suggesting different cellular models that are valuable in evaluating potential drug targets in modulating the disease course in Parkinson's disease. Undeniably, the immortalized SH-SY5Y human neuroblastoma cell lines have been an excellent In the present study, we performed label-free global protein pro ling of terminally differentiated SH-SY5Y (differ-SH-SY5Y) neural cells and the cell model of PD using 6-hydroxydopamine-induced neurodegeneration of differ-SH-SY5Y cells based on a shotgun proteomic methodology. The main objective of this study was to identify the novel biomarkers and pathways involved in the neuronal development of SH-SY5Y cells and the cellular model of PD. The functional role and enriched canonical pathway of the differentially expressed proteins identi ed from these studies were further explored using bioinformatic tools. This study further authenticates the use of the 6-OHDA induced cytotoxicity on differ-SH-SY5Y cell model as an important tool in the investigation of potential drug targets for PD.

Differentiation of SH-SY5Y neuroblastoma cells
The establishment of differ-SH-SY5Y neural cells was performed by seeding 1 x 10 5 cells/mL of SH-SY5Y human neuroblastoma cells in a complete culture medium in a T75 ask. After 24 hours of cell seeding, the cells were exposed to a differentiation medium containing 95% of DMEM, 3% heat-activated FBS, 1% P/S, 1% NEAA and 10 μM of all trans-retinoic acid (RA, Sigma Aldrich, St. Louis, U.S.A) for 6-days. After 6days of the differentiation phase, the differ-SH-SY5Y neural cells express dopaminergic characteristics at morphological, biochemical and genetic levels (Magalingam et al. 2020).
Preparation and Treatment protocol of 6-hydroxydopamine (6-OHDA) 6-Hydroxydopamine (6-OHDA, Sigma Aldrich, St. Louis, U.S.A) was freshly prepared using chilled 0.15% ascorbic acid (Sigma Aldrich, St. Louis, U.S.A) and sterilized by ltering through a syringe lter tted with a 0.2 mM lter and stored in the dark at 4 o C to protect it from light. On day 7 (after the 6-days of differentiation phase), the differ-SH-SY5Y cells were exposed to 10 μg/mL of 6-OHDA in a serum-free culture medium for 24 hours. The undifferentiated cells were maintained in a serum-free culture medium without 6-OHDA for the same duration of time. The concentration of 6-OHDA (10 μg/mL) was selected based on the preliminary studies that showed that it inhibited proliferation of the differ-SH-SY5Y neural cells by about 50%.

Protein extraction
On day 8, the undifferentiated, differ-SH-SY5Y, and 6-OHDA exposed differ-SH-SY5Y neural cells were harvested from the T75 asks and recovered by centrifugation (1000 g for 10 min at 4 o C). The supernatant was discarded, and the total protein was extracted from the cells using the EasyPrep Mini MS Sample Prep kit (Thermo Fisher Scienti c, U.S.A). Brie y, 100 µL of lysis buffer (provided with the kit) and 1 µL of universal nuclease (provided with the kit) were added to the cell pellets and thoroughly mixed until the sample's viscosity reduced. The extracted protein samples were aliquoted and stored at -80°C until further use.

Determination of protein concentration
The extracted proteins' concentration was estimated using the Pierce BCA Protein Kit (Thermo Fisher Scienti c, U.S.A) (El-Rami et al. 2017). The absorbance was measured at 562 nm using a microplate reader (SpectramaxM, CA, USA). A standard curve was prepared by plotting the average corrected absorbance measurements of BSA standards vs concentration in µg/mL to determine the 'unknown samples' protein concentrations.

Protein reduction and alkylation
The extracted proteins were subjected to reduction and alkylation steps followed by protein digestion and a "clean-up" procedure using the EasyPrep Mini MS Sample Prep kit protocol. The samples were removed from the -80°C freezer and thawed at room temperature. Once samples were lique ed, 100 µg of protein from each sample was transferred into appropriately labelled sterile 1.5 mL tubes, and the nal volume for each sample was adjusted to 100 µL with lysis solution (provided with the kit). Then, 50 µL of reduction solution (provided with the kit) was added to each tube and mixed gently. Following this, 50 µL of alkylation solution (provided with the kit) was added to the tubes, and the tubes were gently mixed. The tubes were incubated at 95°C using a heat block for 10 minutes to reduce and alkylation reactions.
Following this, the samples were removed from the heat block to cool to room temperature and subjected to Trypsin/Lys-C protein digestion procedure.

Trypsin/Lys-C protein digestion
For the digestion step, 500 µL of the enzyme reconstitution solution (provided with the kit) was added to a vial containing Trypsin/Lys-C-Protease mix (provided with the kit). Then, 50 μL of the reconstituted Trypsin/Lys-C-Protease mix was added to each tube containing the samples, and the tubes were incubated at 37°C with shaking for 3 hours to allow protein digestion to take place. At the end of 3 hours, 50 µL of digestion stop solution (provided with the kit) was added to each tube to terminate the digestion process.

Peptide clean-up
After the peptide digestion, any contaminants present in the samples were sequentially removed using the peptide clean-up column (provided with the kit). The peptide clean-up columns were labelled accordingly to avoid any sample mix-ups. As per the manufacturer recommended protocol, the white cap at the bottom of each peptide clean-up column was removed, and its green top cap loosened before each clean-up column was placed in individual 2 mL tubes. The tubes were centrifuged (3000 g for 2 minutes) to remove trapped liquid from the column, and the ow-through from each column was discarded. The digested peptides from each sample were transferred into the respective peptide clean-up column. The columns were centrifuged (1500 g for 2 minutes), and the ow-through from each column was discarded. Next, wash solution A (provided with the kit) was added into each column before centrifugation, and the ow-through from each column was discarded. This step was repeated using wash solution B (provided with the kit). Before the elution step, the peptide columns were centrifuged to remove any residual uid. Then, each column was placed on appropriately labelled sterile collection tubes, and elution solution (provided with the kit) was added to each column. The eluted peptide samples were collected by centrifugation, dried using a vacuum centrifuge and stored at -80°C before LC-MS/MS analysis.

Liquid Chromatography and Mass Spectrometry Analysis
The digested peptides were loaded into an Agilent 1200 HPLC-Chip/MS Interface, coupled with Agilent 6550 iFunnel Q-TOF LC/MS (Agilent, Santa Clara, CA, USA). The column was equilibrated with 0.1% formic acid in water (solution A). The peptides were eluted from the column with 90% acetonitrile in 0.1% formic acid in water (solution B). Quadrupole-time of ight (Q-TOF) polarity was set at positive with capillary and fragmenter voltage being set at 1900 V and 360 V, respectively, and 5 L/min of gas ow with a temperature of 325 •C. The collision energy was determined at 3.7V (100Da), and reference masses with positive polarity was set at 299.294457 and 1221.990637. The peptide spectrum was analysed in auto MS mode ranging from 110-3000 m/z for MS scan and 50-3000 m/z for MS/MS scan.

Data Computation
The raw data of tryptic peptides were extracted and processed using PEAKS X software (Bioinformatics Solutions Inc., Waterloo, ON, Canada) using Uniprot, Swissprot and TrEMBL databases. The PEAKS X software allows for the determination of the protein abundance using the following search parameters: retention time lower bound: ≥ 0, retention time upper bound: ≤ 55, average area: ≥ 0, charge lower bound: ≥ 1, con dent number samples per group: ≥ 1, peptide identi cation count: ≥ 1, protein signi cance: ≥ 20, used peptides: ≥ 1, xed modi cation: Carbamidomethylation of cysteine residues and false discovery rate (FDR): 1% in three biological replicate injections. Protein abundance was computed using normalized spectral protein intensity (LFQ intensity). The obtained peptide/protein list was exported to Microsoft Excel to quantitate three biological replicates from the same samples were grouped in the same matrix. The protein data were ltered for at least two valid values, and protein only presented in one biological replicate was eliminated. The biological replicates from all samples were clustered under the same matrix, and the missing data were assigned with a random number derived from a normal distribution. The reason for the missing data measurement is due to low protein abundance in LC-MS/MS analysis.

Biocomputational Protein analysis
Protein Functional classi cation was performed using the gene ontology database The identi ed proteins with p<0.05 against their respective control were classi ed based on (i) molecular function, (ii) biological process and (iii) cellular component using Gene Ontology (GO) term analysis. The online bioinformatics tool PANTHER database (http://pantherdb.org) version 16 was used to elucidate the functions of these differentially expressed proteins in the differ-SH-SY5Y neural cells and 6-OHDA exposed differ-SH-SY5Y cells. Only the top 10 enriched GO terms were listed for each functional classi cation. All results displayed expressed adjusted p-value < 0.05 as determined by Fischer's Exact test and FDR.

Protein-Protein Interaction (PPI) Analysis
The STRING database (STRINGv11.0) (https://string-db.org) was used to construct the PPI network in neuronal maturation and oxidative stress in 6-OHDA treated neural cells based on its physical binding and regulatory interaction. The Uniprot IDs of the differentially regulated proteins were inputted in the STRING database under the multiple protein analysis categories and followed by the selection of Homo Sapiens from organism pull-down selection. The basic settings that were used in the analysis of PPI are Network type: Full network, active interaction sources: text mining, neighbourhood, experiments, databases, co-expression, gene-fusion, co-occurrence, Minimum required interaction score: highest con dence (0.9) and K-mean clustering was speci ed as three clusters. Thick edges between the protein nodes demonstrate strong protein interaction. This protein cluster was uploaded into Cytoscape 3.8.0 to visualise the complex networks by integrating Log2 fold-change data.

Pathway Enrichment Analysis
The pathway enrichment analysis of the differentially expressed proteins was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery, https://david.ncifcrf.gov/) bioinformatic online database. The cluster with the most enriched proteins exhibiting strong PPI identi ed from STRING analysis was uploaded as an o cial gene symbol in DAVID resources. The enriched pathway curated by KEGG (Kyoto Encyclopaedia of Genes and Genomes) was used to elucidate the differentially regulated protein molecular mechanisms.

Statistical analysis
Statistical analysis comparing the quantitative data from differential protein expression between differ-SH-SY5Y neural cells vs undifferentiated SH-SY5Y cells and 6-OHDA treated differ-SH-SY5Y neural cells vs untreated differ-SH-SY5Y cells were performed using a two-tailed Student's t-test. All statistical analyses were performed with GraphPad Prism version 9.0. Differentially expressed proteins that displayed the difference in Log2 Fold change (< or > 0) with p<0.05 were regarded as statistically signi cant.

Label-Free Spectrometry Identi cation and Quanti cation of differentially regulated proteins
The protein pro ling of differ-SH-SY5Y neural cells vs undifferentiated SH-SY5Y cells and 6-OHDA induced neurodegeneration vs untreated differ-SH-SY5Y were analysed using PEAKS X + software. The label-free tandem liquid mass spectrometry (LC-MS/MS) identi ed a total of 3261 and 3873 proteins for the differentiated and undifferentiated SH-SY5Y neural cells, respectively. Around 687 and 941 proteins were common in all the biological triplicates in differ-SH-SY5Y and undifferentiated SH-SY5Y cells, respectively. When we compared the standard protein sets between differentiated and undifferentiated SH-SY5Y neural cells, we found a total of 189 (Table 1) Fig. 1 (A)). On the other hand, the 6-OHDA treated differ-SH-SY5Y neural cells yielded 3636 proteins with 293 proteins shared the common data sets. When the protein pro les from the 6-OHDA treatment were compared with that of the untreated differentiated SH-SY5Y cells, a total of 188 proteins matched both protein data sets with a total of 101 proteins ( Table 2) exhibited statistical signi cance difference. Among 101 signi cantly regulated proteins, 63 proteins upregulated, and 38 proteins downregulated. The Log2 fold-change distribution of differentially regulated proteins displays three proteins with the difference of 1-fold change [VDAC1 (Voltage-dependent anion-selective channel protein 1), HSPA9 (Stress-70 protein mitochondrial), HSPE1 (10 kDa heat shock protein mitochondrial)], 15 proteins with a 0.5-1 fold-change difference, 84 proteins showing 0.5-1 fold-change and 86 proteins with no statistical difference fold-change ( Fig. 1(B)).

Biocomputational Analysis of differentially regulated proteins
Functional Annotation Analysis of differentially regulated proteins using PANTHER To further elucidate the changes in cellular processes, the gene ontology (GO) analysis of the 86 differentially expressed proteins (p < 0.05) in the differ-SH-SY5Y neural cells were investigated using the PANTHER bioinformatics database. These proteins were analysed based on changes in the GO term classi cation clusters' biological process, molecular function, and cellular component. The GO-molecular function of differ-SH-SY5Y neural cells showed a strong correlation to the structural modulation, activity and binding of ribosomes and ribosomal proteins. As for the GO-biological process, the differentially expressed proteins modulated the ribosomal assembly, biogenesis, glycolytic process (ATP generation) and DNA synthesis (purine nucleoside and ribonucleotide diphosphate phosphorylation and metabolic process). These molecular and biological processes were identi ed as concentrated at cytosolic ribosome units, as shown in the GO-cellular component (Fig. 2 (A)).
Next, for the 6-OHDA induced neurodegeneration in differ-SH-SY5Y, the GO-molecular function showed the association of the dysregulated proteins to the DNA structural alterations (structural molecule, purine, nucleoside, nucleotide), changes in structural constituents of ribosomes, metabolic processes (carbohydrate derivative binding), calcium cell signalling pathway (Calcium ion binding), metal ion homeostasis (metal ion binding) and unfolded protein binding. For the GO-biological process, the analysis revealed 6-OHDA induced neurodegeneration causes enrichment of the cellular mechanisms that identify and respond to misfolded/unfolded proteins (i.e., protein folding, cellular response to topologically incorrect protein, cellular response to unfolded proteins, endoplasmic reticulum unfolded protein response), metabolic activity (glycolytic activity, ATP generation), DNA structural changes (purine ribonucleoside diphosphate metabolic process) and apoptotic nucleosome assembly. The proteins localized in GO-cellular components were identi ed to be mitochondria (i.e., proton-transporting ATP synthase complex, mitochondrial prohibitin complex, mitochondria cristae), neuronal synapse or ribbon synapse (dense body), ribosome (i.e., eukaryotic translation elongation factor 1 complex, cytosolic RNA splicing (pIC1n-Sn protein complex, U7 snRNP) and endoplasmic reticulum (Fig. 2 (B)).
STRING Protein-protein interaction (PPI) networks analysis of differentially regulated proteins using STRING.

Discussion
In this study, the differentially expressed proteins in differ-SH-SY5Y neural cells and the cellular model of PD were identi ed, and the alteration of the proteome was assessed through the enrichment of molecular functions, biological processes, and cellular pathways. Our ndings showed that the RA induced differentiation of SH-SY5Y cells exhibited a signi cant increase in the expression of two crucial proteins, calnexin and calreticulin proteins (Fig. 1(A)). Calreticulin, an essential Ca 2+ binding chaperone in the endoplasmic reticulum, is a vital entity of the calreticulin/calnexin cycle (Xiao et al. 2017). Nevertheless, the calreticulin/calnexin cycle plays a crucial role in folding newly synthesized proteins for cellular differentiation or organ development (Dudek and Michalak 2013). Emerging studies have shown that calreticulin mediated suppression of oncogenic N-MYC (MYCN) resulted in increased neurite length and differentiation marker GAP-43 (Lee et al. 2019). A study on the calreticulin knock-out mouse model displayed embryonic lethality with remarkable defects in the heart, brain and body wall, suggesting the pivotal role of calreticulin in developing the nervous system (Rauch et al. 2000). On the other hand, calnexin's role has been associated with nerve cells' myelination as being de cient in the calnexin gene leads to myelinopathy (Kraus et al. 2010). Hence, the expression of these proteins in differ-SH-SY5Y neural cells signi es the activation of neuronal features such as myelination and suppression of oncogenic characteristics of neuroblastoma cells.
The differ-SH-SY5Y neural cells also demonstrated a signi cant 1-fold down-regulation of DDX39B and ribosomal proteins, RPS12, RPL10, RPL12 and RPSA. The DDX39B is a member of the DEAD-box family of RNA helicases that plays a pivotal role in pre-mRNA splicing and mRNA export to the cytoplasm (Zhang et al. 2018). Intrinsically, the DDX39B promotes the unwinding of the U4/U6 snRNA duplex, which in-turn permits the binding of the U2 snRNP to the pre-mRNA in a series of ATP-dependent pre-mRNA splicing process (Shen et al. 2008). Consequently, DDX39B mediates the nuclear transport of mRNA by facilitating the interaction between THO complex and CIP29 and Aly (nuclear factors) (Folco et al. 2012).
The interaction between the DDX39B with export proteins CIP29 and Aly during the formation of the conserved TREX mRNA export complex is controlled by ATP hydrolysis (K et al. 2010). A recent study has reported that the increased pre-ribosomal RNA levels of DDX39B augment global translation and cell proliferation of diverse cancer types. This study also showed that DDX39B knockdown cells displayed a signi cantly reduced stability of pre-ribosomal 47S RNA, whereas the 47S rRNA stability was unaltered in DDX39B overexpressed cells (Awasthi et al. 2018). The present study's ndings suggest that the downregulation of DDX39B in differ-SH-SY5Y neural cells is closely linked to the suppression of ribosomal proteins and RNA biogenesis. The inhibition of cell proliferation in differentiated neural cells was caused by the suppression of ribosomal proteins that play a crucial role in protein biosynthesis and cell growth. Evidence supporting this nding comes from a study by Linstrom et al. that suggested that silencing of ribosomal protein S9 (RPS9) elicits cell proliferation restriction mediated by the p53 tumour suppressor pathway in cancer cells. This study also pointed out that the suppression of ribosomal proteins effectively promotes differentiation processes, senescence, or apoptosis in rapidly propagating cancer cells (Lindström and Nistér 2010). According to our STRING PPI analysis, a total of 28 differentially regulated proteins were found to form the most prominent network in cluster II. Among these, 21 ribosomal proteins displayed a signi cant down-regulation in differ-SH-SY5Y neural cells compared to undifferentiated SH-SY5Y cells (Fig. 4 (A&B)). These 21 ribosomal proteins were identi ed to have a pivotal role in the ribosome bio-pathway as curated by the KEGG database.
The ribosome is the cellular translational machinery's principal component that decodes messenger RNA (mRNA) to produce an amino acid chain through a complementary anticodon sequence (Guimarães 2017). The manufacture of this machinery component is known as ribosome biogenesis and occurs in the nucleolus via initiation by the RNA-polymerase-1 (RNA-pol1) that mediates the transcription of rRNA genes (Drygin et al. 2010). Three RNA polymerase enzymes, RNA-pol1, RNA-pol2, RNA-pol3 and nonribosomal factors, were responsible for generating the 90S pre-ribosomes in the nucleolus undergoes several modi cations before splitting into pre-60S and pre-40S particles (Torreira et al. 2017). These particles mature into the large (60S) and small (40S) subunits for protein synthesis during the transportation from nucleolus into cytoplasm compartments through dissociation from most of the nonribosomal factors (Delavoie et al. 2019). Emerging studies have revealed that ribosome biogenesis and protein translations are exceptionally synchronized with cellular processes, including cell division, differentiation and growth (Zhou et al., 2015). Disruption in any of these two dynamic processes could impede the crucial cellular biological processes and well-being.
Furthermore, recent pieces of evidence have documented that down-regulation of the ribosomal proteins (RPs) and translation e ciency during the differentiation process contribute to reduced cell growth and THP-1 cells differentiation potential. The attenuation of rRNA transcription was shown to enhance the cell differentiation in both cell lines and increase the differentiation marker, CD11b. They also evaluated if cell differentiation was triggered by inhibition of the cell cycle since rRNA transcription is tightly paired with cell growth. The outcome of this study showed that cell cycle arrest that occurred without affecting rRNA transcription did not stimulate differentiation in mouse hematopoietic stem cells (Hayashi et al. 2014). This data is in line with our ndings that showed a signi cant down-regulation of RPs in differ-SH-SY5Y cells indicate the augmentation in the differentiation mechanism and suppression of cell growth compared to undifferentiated SH-SY5Y neuroblastoma cells.
The neurotoxin 6-OHDA induced neurodegeneration model is a well-acknowledged neurodegenerative "simulation" conceived by the PD research community to study the disease cellular and molecular processes, both in vitro or in vivo settings (Xicoy et al. 2017). Although the model does not demonstrate the classical pathological hallmark of PD, which is the accumulation of α-synuclein and Lewy bodies, it expresses the cardinal processes in PD, including mitochondrial dysfunction, apoptosis, ROS induced oxidative stress, neuro-in ammation, lipid peroxidation and disruption in endogenous antioxidant enzymes (Dias et al. 2013). In our study, the 6-OHDA exposure on the differ-SH-SY5Y neural cells revealed a remarkable 1-fold change overexpression of VDAC1, HSPE1 and HSPA9 proteins (Fig. 1 (B)). protein expression in our nding indicates that the 6-OHDA treated differ-SH-SY5Y neural cells underwent rigorous oxidative stress-induced apoptosis, which is an expected outcome in a PD disease model.
The heat shock proteins (HSPs) are the most conserved 10kDa evolutionary proteins known as stressinducible proteins. The HSPE1 (HSP10) is found abundantly in mitochondria, whereas HSPA9 (HSP70) exists in the cytoplasm and nucleus. Generally, HSPs functions as cytoprotective proteins with related cochaperones under increased free radicals induced apoptosis through the initiation of a repair mechanism and refolding of misfolded peptides, possible proteolysis of irreparable proteins, signalling transduction and translocation (Sharma et al. 2012). Principally, the HSPA9 assists in the transportation of nuclearencoded proteins to the mitochondria and these proteins are subsequently refolded by HSPD1(HSP60) and its co-chaperone, HSPE1 (Voos 2013). The HSPD1-HSPE1 complex chaperonin consists of two rings arranged to conform to a barrel-shaped structure with a central cavity. This complex receives the unfolded or misfolded proteins into its central cavity and facilitates the folding process divided into three steps. In the rst step, the HSPD1-HSPE1 complex binds rmly with the unfolded or misfolded proteins; then the proteins get trapped in the central cavity capped by HSPE1 refolding of the protein takes place.
Finally, the correctly folded proteins are ejected from the chaperonin complex. The unfolded or partially folded proteins are redirected to the chaperonin to repeat the entire cycle until the correctly folded proteins are achieved (Jia et al. 2011). While the HSPD1 and HSPE1 are crucial housekeeping proteins for e cient mitochondria function and biogenesis, the HSPA9 is best known for its cytosolic chaperone activity in assisting protein folding, degradation and translocation. Overwhelming evidence has pointed out that HSPs have been identi ed to be involved in multiple pathways in promoting the anti-apoptosis effect (Ikwegbue et al. 2018). According to Li et al., the chaperone activity of HSPA9 is crucial for the inhibition of caspase activation at a reaction point between the cytochrome c release and caspase-3 activation (Li et al. 2000). The overexpression of HSPA9 was also reported to indirectly inhibit the stress-induced apoptosis by preventing the conformational change and translocation of Bax into mitochondria, indicating the suppression of apoptosis through Bax inactivation and inhibition of caspase activation (Stankiewicz et al. 2005). A recent study has clari ed that overexpression of HSPA9 prevents in ammation in a rat model of intracerebral haemorrhage through inhibition of in ammatory cytokines such as TNF-α, IL-β, Bax and increased Bcl-2 levels (Lv et al. 2017). Hence, we postulate that the overexpression of HSPE1 and HSPA9 in our study is closely connected to the cytoprotective mechanism of the neuronal cells to inhibit the avalanche of apoptotic mediators released in response to 6-OHDA treatment. HSP expression in the PD cell model is an important biomarker that paves the way for future studies in developing potential therapies targeting the HSPE1 and HSPA9 to mitigate apoptosis-induced cell death.
The treatment of 6-OHDA induced neurodegeneration on differ-SH-SY5Y neural cells resulted in an enrichment of 4 clusters or pathways in STRING PPI analysis (Fig. 3(B)). The crosstalk between proteins populated in cluster IV of STRING PPI displaying the most prominent interaction was further investigated using KEGG pathway enrichment analysis. The KEGG bioinformatic pathway enrichment database predicted the systemic lupus erythematosus (SLE) pathway with the involvement of 17 out of 19 upregulated proteins (Fig. 5(A) and (B)). SLE is an autoimmune disease of unknown aetiology that primarily affects women in the childbearing age (Pieterse and van der Vlag 2014). The disease is characterized by disturbances of the immune system that arise when the immune cells respond to selfantigens, mainly nuclear constituents, i.e., histones, ribonucleoproteins and DNA (Pradhan et al. 2010). For over two decades, apoptosis has been regarded as a signi cant source of autoantigens in SLE.
Apoptosis can be actively triggered by ligation of cell surface receptors, including Fas and tumour necrosis factor receptor (TNFR) or passively via de cient in crucial cell survival signals (De Wilde et al. 2001). Apoptotic cells undergo an orderly process of morphological alterations, such as nuclear chromatin condensation, nuclear splitting, cytoskeletal disruption, cell shrinkage and membrane blebbing (Saraste and Pulkki 2000). Persistent exposure of the immune system to apoptotic bodies leads to the formation of an anti-chromatin/chromatin complex, triggering an array of in ammation in multiple organs in SLE patients. Previous studies have shown that autoantibodies' increased reactivity against histone proteins, namely histone H4 and H2B peptides, correlated with SLE disease activity (Dieker et al. 2016). Whereas in PD, the selective vulnerability of dopamine neurons to environmental toxins, intracellular accumulations of highly oxidative free radical and toxic accumulation of misfolded proteins leads to neurodegeneration (apoptosis) and activation of neuro-in ammation pathway (Hald and Lotharius 2005). As such, the neuro-in ammation pathway is triggered through activation of microglia or the "immune cell of the brain", which releases the pro-in ammatory mediators including tumour necrosis factor (TNF-α), interleukin (IL-1β), IL-2, IL-4, interferon (IFN-γ) and nitric oxide (NO) (Liu et al. 2019). The pro-in ammatory mediators instigate further detrimental effects on nigral neurons by causing direct toxicity in neurons and induce ongoing neuro-in ammation through microglial NO activation (Jung et al. 2019). Emerging studies have reported that chronic SLE patients presented with parkinsonian syndromes, including slowness in movement, adiadochokinesia, postural rigidity and tremor (Fabiani et al. 2002).
In our study, the histone proteins were shown to be exceptionally overexpressed in 6-OHDA induced neurodegeneration on differ-SH-SY5Y neural cells (PD cell model). Structurally, histone proteins exist as an octamer with two copies of each of the four core histone proteins H2A, H2B, H3 and H4 and two linker histones, H1 and H5 (Andrews and Luger 2011). The 147bp of DNA packages the octamer histones to form a nucleosome. The four core histones form a conserved central motif domain known as histone fold composed of a long central α-helix structure with a short helix anked on either side (Jiang and Pugh 2009). In comparison, the linker histone associates with nucleosome to transform nucleosomes into various high-order chromatin structures. Ideally, the histone proteins function in constructing the nucleus and ne-tuning gene expression for physiological and pathological processes (Martire and Banaszynski 2020). An increasing body of evidence suggests that besides regulating nucleosome dynamics, histone proteins are released in the extracellular eld by cells undergoing apoptosis (Silk et al. 2017).
It is well established that chromatin condensation coupled with DNA fragmentation is important nuclear events during apoptosis (He et al. 2009). In response to apoptotic signals, the core and linker histones are detached from genomic DNA and released into cytoplasmic and extracellular regions. Wu  In conclusion, the PD cell model is an essential in vitro platform for investigating the molecular and biological processes involved in the disease process and paving the way for future discoveries of potential therapeutic drugs that reverse these mechanisms. Ideally, a disease model should express the biomarkers that indicate the progression of PD's pathological conditions such as mitochondrial dysfunction, DNA fragmentation, neurodegeneration, and neuro-in ammation. The differ-SH-SY5Y neural cells developed from SH-SY5Y human neuroblastoma cells expressed substantial dopaminergic markers and, upon perturbation with 6-OHDA, displayed pathological changes frequently detected in PD. The differentially regulated proteins were analysed using GO functional annotation, STRING PPI and KEGG pathway enrichment databases to understand the cellular machinery's alterations during the disease process. We suggest that the down-regulation of the ribosome pathway promotes the differentiation of neuronal cells. In contrast, the neurodegeneration process is mediated by nucleosomal degradation demonstrated by the upregulation of histone products in the SLE pathway as a signi cant PD event.

Declarations
Ethics approval and consent to participate: Not Applicable the base of 10). Proteins that are 1-fold signi cantly regulated are presented as red dots, while those that had 0.5 to 1-fold change are shown as blue dots. Proteins with fold change less than 0.5-fold change are presented as grey dots. Black dots represent proteins that do not have a statistically signi cant foldchange.

Supplementary Files
This is a list of supplementary les associated with this preprint. Click to download. Table1andTable2.pdf